desmopressin acetate (redirected from Octostim)

des·mo·pres·sin acetate (dsm-prsn)

n.

An analog of vasopressin, used as an antidiuretic and to manage bleeding in some forms of hemophilia and in von Willebrand's disease.

---

desmopressin acetate

[dez′mōpres′in]

a synthetic antidiuretic analog of arginine vasopressin, the naturally occurring human antidiuretic hormone.

indications It is prescribed as an antidiuretic in the treatment of diabetes insipidus and primary nocturnal enuresis and is used to control bleeding in hemophilia A and mild von Wildebrand's disease.

contraindications Known hypersensitivity to this drug, hemophilia B, and severe von Wildebrand's disease (IIB) prohibit its use.

adverse effects Among the most serious adverse reactions are hyponatremia and water intoxication, which are seen more often when the drug is used for hemostatis. Mild effects, such as headache, cramps, and nasal congestion, also may occur.

---

desmolysis (desmol´isis),

n the destruction and disintegration of connective tissue. Some authorities associate this desmolytic process with the destruction of connective tissue lying between the enamel and oral epithelium, which thus permits proliferation of the oral epithelium and fusion of enamel and oral epithelium.

desmopressin acetate

n brand name: Stimate;
drug class: synthetic antidiuretic hormone;
action: promotes reabsorption of water by action on renal tubular epithelium;
uses: primary nocturnal enuresis, hemophilia A with factor VIII levels of less than 5%, von Willebrand disease, and neurogenic diabetes insipidus.

---

desmopressin acetate (1-deamino-8-D-arginine vasopressin)

Apo-Desmopressin (CA), DDAVP, Minirin, Octostim, Stimate

Pharmacologic class: Posterior pituitary hormone

Therapeutic class: Antidiuretic hormone

Pregnancy risk category B

Action

Enhances water reabsorption by increasing permeability of renal collecting ducts to adenosine monophosphate and water, thereby reducing urinary output and increasing urine osmolality. Also increases factor VIII (antihemophilic factor) activity.

Availability

Injection: 4 mcg/ml in single-dose 1-ml ampules and multidose 10-ml vials

Intranasal solution: 0.1 mg/ml, 1.5 mg/ml

Intranasal spray (DDAVP): 0.1 mg/ml (10 mcg/spray) in 5-ml spray pump bottle

Tablets: 0.1 mg, 0.2 mg

⊘Indications and dosages

➣ Diabetes insipidus

Adults and children older than age 12: 0.05 mg P.O. b.i.d.; adjust dosage based on patient response. Or 0.1 to 0.4 ml (10 to 40 mcg) daily intranasally as a single dose or in two or three divided doses. Or 0.5 ml (2 mcg) to 1 ml (4 mcg) daily I.V. or subcutaneously, usually in two divided doses.

Children ages 3 months to 12 years: 0.05 to 0.3 ml/day intranasally in one or two divided doses

➣ Hemophilia A; von Willebrand's disease type I

Adults and children: 0.3 mcg/kg I.V.; may repeat dose if needed. Or 300 mcg of intranasal solution containing 1.5 mcg/ml; for patients weighing less than 50 kg (110 lb), total dosage of 150 mcg (one spray of solution containing 1.5 mg/ml into a single nostril) is usually sufficient. If needed to maintain hemostasis during surgery, give intranasal dose 2 hours before surgery or give I.V. dose 30 minutes before surgery.

➣ Primary nocturnal enuresis

Children ages 6 and older: Initially, 20 mcg intranasally at bedtime. Maximum dosage is 40 mcg/day.

Off-label uses

• Chronic autonomic failure (such as nocturnal polyuria, overnight weight loss, morning orthostatic hypotension)

Contraindications

• Hypersensitivity to drug
• Moderate to severe renal impairment
• Hemophilia A with factor VIII levels less than or equal to 5%
• Von Willebrand's disease type IIB
• Impaired level of consciousness (intranasal form)

Precautions

Use cautiously in:
• coronary artery disease, hypertensive cardiovascular disease, fluid and electrolyte imbalances
• breastfeeding patients.

Administration

• Adjust morning and evening dosages as appropriate to minimize frequent urination and risk of water intoxication.
• Give I.V. dose (diluted in normal saline solution) by infusion over 15 to 30 minutes.
• Monitor pulse and blood pressure throughout I.V. infusion
☞ When giving to child with diabetes insipidus, carefully restrict fluid intake to prevent hyponatremia and water intoxication.

Route	Onset	Peak	Duration
P.O.	1 hr	1-5 hr	8-12 hr
I.V.	15-30 min	Unknown	4-12 hr
Intranasal	1 hr	1-1.5 hr	8-12 hr

Adverse reactions

CNS: headache, dizziness, insomnia

CV: slight blood pressure increase, chest pain, palpitations

EENT: rhinitis, epistaxis, sore throat

GI: nausea, abdominal pain

GU: vulvar pain

Respiratory: cough

Other: local erythema, flushing, swelling or burning after injection

Interactions

Drug-drug. Carbamazepine, chlorpropamide, pressor drugs: potentiation of desmopressin effects

Patient monitoring

• Monitor urine volume and specific gravity, plasma and urine osmolality, and electrolyte levels in patients with diabetes insipidus.
• Monitor factor VIII antigen levels, activated partial thromboplastin time, and bleeding time in patients with hemophilia.
☞ When giving to child with diabetes insipidus, carefully monitor fluid intake and output.

Patient teaching

• Instruct patient to take drug exactly as prescribed and not to interchange strengths or delivery systems.
• Teach patient how to use prescribed delivery system if taking drug by other than oral route.
• Instruct patient with diabetes insipidus to avoid overhydration and to weigh himself daily. Tell him to report weight gain or swelling of arms or legs. If he's using nasal spray, teach him to inspect nasal membranes regularly and to report increased nasal congestion or swelling.
• Caution elderly patient not to increase fluid intake beyond that sufficient to satisfy thirst.
• As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs mentioned above.